



Final Appraisal Recommendation
Advice No: 2416 – September 2016

Green tea leaf extract (Catephen®) 10% Ointment

Submission by Kora Healthcare

Recommendation of AWMSG

Green tea leaf extract (Catephen®) is recommended as an option for restricted use within NHS Wales.

Green tea leaf extract (Catephen®) is licensed for the cutaneous treatment of external genital and perianal warts (condylomata acuminata) in immunocompetent patients from the age of 18 years.

Green tea leaf extract (Catephen®) is restricted for use in patients not suitable for podophyllotoxin or who have not responded to treatment with podophyllotoxin.

Green tea leaf extract (Catephen®) is not recommended for use within NHS Wales outside of this subpopulation.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2739), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Kora Healthcare
Date of first issue	September 2016
Last reviewed	August 2020

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2416:
Green tea leaf extract (Catephen®) 10% Ointment. September 2016.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at <http://www.nice.org.uk/about/what-we-do/accreditation>